The FDA this week announced a new "risk evaluation and mitigation strategy" for extended-release and long-acting opioids, targeting safety measures at more than 20 companies that manufacture the drugs.
Drug manufacturers will be required to offer opioid education programs to prescribers and create FDA-approved patient education materials that address the safe use of the drugs.
The first continuing education activities under the REMS will be offered to prescribers by March 1, 2013, according to an agency release.
Pain and Spine Specialists of Maryland Launches New Clinic
Purdue Pharma Plans Pediatric OxyContin Trial
Drug manufacturers will be required to offer opioid education programs to prescribers and create FDA-approved patient education materials that address the safe use of the drugs.
The first continuing education activities under the REMS will be offered to prescribers by March 1, 2013, according to an agency release.
Related Articles on Pain Management:
Pain Management Physician to Join Neuroscience ClinicPain and Spine Specialists of Maryland Launches New Clinic
Purdue Pharma Plans Pediatric OxyContin Trial